67853-37-6

Basic information

• Product Name: 2-Bromo-3-nitroanisole
• Synonyms: 2-BROMO-1-METHOXY-3-NITROBENZENE;2-BROMO-3-NITROANISOLE;TIMTEC-BB SBB008642;2-Bromo-3-nitroanisole 99%;2-Bromo-3-methoxynitrobenzene;2-Bromo-3-methoxynitrobenzene, 2-Bromo-1-methoxy-3-nitrobenzene, 2-Bromo-3-nitrophenyl methyl ether
• CAS NO: 67853-37-6
• Molecular Formula: C₇H₆BrNO₃
• Molecular Weight: 232.03
• Product Categories: Anisole;Anisoles, Alkyloxy Compounds & Phenylacetates;Bromine Compounds;Nitro Compounds
• Mol File: 67853-37-6.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 273.274 °C at 760 mmHg
• Flash Point: 119.072 °C
• Appearance: /
• Density: 1.64 g/cm³
• Vapor Pressure: 0.01mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-Bromo-3-nitroanisole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-3-nitroanisole(67853-37-6)
• EPA Substance Registry System: 2-Bromo-3-nitroanisole(67853-37-6)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 20/21/22-22
• Safety Statements: 26-36/37/39
• Hazardous Substances Data: 67853-37-6(Hazardous Substances Data)

Usage

General Description

2-Bromo-3-nitroanisole is an organic compound consisting of a bromine atom, a nitro group, and a methoxy group attached to a benzene ring. It is commonly used as an intermediate in the production of pharmaceuticals and agrochemicals. 2-Bromo-3-nitroanisole is known to possess significant antimicrobial and anti-inflammatory properties, making it a valuable building block in the synthesis of various bioactive molecules. Additionally, 2-Bromo-3-nitroanisole has been found to exhibit potential as a corrosion inhibitor in metalworking processes. However, it is important to handle this chemical with caution as it is classified as a hazardous substance due to its toxic and irritant properties.

InChI:InChI=1/C7H6BrNO3/c1-12-6-4-2-3-5(7(6)8)9(10)11/h2-4H,1H3

Upstream product

• 101935-40-4 2-bromo-3-hydroxy-1-nitrobenzene 
• 74-88-4 methyl iodide 
• 603-85-0 2-Amino-3-nitrophenol 
• 16554-45-3 2-methoxy-6-nitroaniline 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 112970-44-2 2-bromo-3-methoxyaniline 
• 4837-90-5 4-methoxy-1H-indole 
• 112970-67-9 4-methoxy-1-<(4-methylphenyl)sulfonyl>indole 
• 112970-49-7 2-bromo-3-methoxy-N-tosylaniline 
• 112970-54-4 2-ethenyl-3-methoxy-N-(p-tolylsulfonyl)aniline 
• 528-71-2 phenazin-1-ol 
• 2876-17-7 1-methoxyphenazine 
• 1202661-27-5 2-(6'-methanesulfonyl-2'-pyridin-4-yl-biphenyl-4-yloxymethyl)-quinoline 
• 1202676-60-5 6-pyridin-4-yl-4'-(quinolin-2-ylmethoxy)-biphenyl-2-ylamine 
• 1202661-19-5 2-(2'-nitro-6'-pyridin-4-yl-biphenyl-4-yloxymethyl)-quinoline 

Relevant articles and documents

LIPOXYGENASE INHIBITORS

Various embodiments of the present disclosure are directed to compounds having Formula (I), Formula (IA), Formula (IB), Formula (IC), Formula (ID), Formula (IE), and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases, and/or treating associated diseases, such as Alzheimer's disease. In some embodiments, the compounds may be administered to a patient as part of a pharmaceutical formulation.

HEPATITIS C INHIBITOR PEPTIDE ANALOGS

The compounds of formula I wherein R1, R2, R3 , R4 and R5 are defined herein, are useful as inhibitors of the hepatitis C virus NS3 protease The invention further relates to azalactone compounds of the formula (II) which can be reacted with an amide anion to produce the HCV NS3 protease inhibitors of formula (I)

HEPATITIS C INHIBITOR DIPEPTIDE ANALOGS

The present invention relates to compounds of formula (I): wherein R1, R2, R4, n and m are as defined herein and R3 is selected from: (i) -C(O)OR31 wherein R31 is (C1-6)alkyl or aryl, wherein the (C1-6)alkyl is optionally substituted with one to three halogen substituents; (ii) -C(O)NR32R33, wherein R32 and R33 are each independently selected form H, (C1-6)alkyl, and Het; (iii) -SOvR34, wherein v is 1 or 2 and R34 is selected from: (C1-6)alkyl, aryl, Het, and NR32R33 wherein R32 and R33 are as defined above; and (iv) -CO(O)-R35, wherein R35 is selected from (C1-8)alkyl, (C3-7)cycloalkyl-(C1-4)alkyl, aryl, aryl-(C1-6)alkyl, Het and Het-(C1-6)alkyl, each of which are optionally substituted with one or more substituents each independently selected from halo, (C1-6)alkyl, (C3-7)cycloalkyl, aryl, Het, hydroxyl, -O-(C1-6)alkyl, -S-(C1-6)alkyl, -SO-(C1-6)alkyl, -SO2-(C1-6)alkyl, -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl, wherein the aryl portion of the -O-aryl, -S-aryl, -SO-aryl and -SO2-aryl are each optionally substituted with one to five halo substituents. The present invention further relates to pharmaceutical compositions containing the compounds of formula (I) and methods for using these analogs in the treatment of HCV infection.